Latest Post

June 11, 2019

Particulate Challenges

Particulates in injectable drug products continue to be an area of great interest in the industry. The main reason is the potential clinical effects on patients, which can range from emboli to inflammations to infections. There are a series of clinical risk factors that should be considered in evaluating and mitigating these challenges. These factors are route of administration, patient population, and particulate composition (i.e., number, size, and shape). All are critical inputs to understanding risk and determining corrective and preventative actions.
Fran DeGrazio

Fran DeGrazio

V.P. Technical Customer Service & Scientific Affairs

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    West logo with Diamond

    April 03, 2012

    West’s Diane Paskiet to Present at PDA Annual Meeting in April

    West Pharma

    Diane Paskiet

    Director, Scientific Affairs